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CONCLUSIONS: Retrospective database analysis has yielded a
previously unavailable resource allocation and cost structure that
illuminates our understanding of severe sepsis management 
economics.
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OBJECTIVE: Although treatment failure can substantially
increase medical-care costs, data on the economic impact of
treatment failure in acute bacterial maxillary sinusitis (ABMS)
are lacking. The absence of these data undermines efforts to
incorporate pharmacoeconomic criteria in clinical decision-
making (beyond simplistic comparisons of the acquisition costs
of competing antibiotics). We conducted this study to document
the cost of treatment failure in ABMS. METHODS: Data were
obtained from a prospective, randomized, double-blind, equiva-
lency study in which adults with radiographic evidence of ABMS
were randomized to treatment with telithromycin 800mg once
a day for 5 days followed by placebo for 5 days (n = 159) or
moxiﬂoxacin 400mg once a day for ten days (n = 163). Patients
were asked to record in a study diary all nonprotocol sinusitis-
related health-care utilization over a 30-day follow-up period,
including outpatient visits, tests and procedures, prescription
medications, and over-the-counter remedies. Unit costs were
assigned to all measures of health-care utilization using nation-
ally representative published sources. All utilization and cost
measures were analyzed irrespective of treatment assignment and
compared between patients who were treatment “successes”
versus “failures”, as assessed for the primary efﬁcacy endpoint.
RESULTS: A total of 253 subjects were declared treatment suc-
cesses and 47 treatment failures. Treatment failures incurred
sinusitis-related medical-care costs that were nearly sixfold
higher than treatment successes ($126.11 vs $21.98; p < 0.001),
reﬂecting higher mean utilization of unscheduled outpatient ser-
vices (0.40 vs 0.10 visits; p = 0.009), tests and procedures (0.32
vs 0.08; p = 0.002), and nonstudy prescription medications (1.23
vs 0.39; p < 0.001). Use of over-the-counter drugs did not differ
signiﬁcantly (0.68 vs. 0.54 units purchased; p = 0.763). CON-
CLUSIONS: The cost of treatment failure in ABMS appears to
be substantial. Clinical decision-making regarding choice of
antibiotic therapy in ABMS should involve consideration of how
treatment failure might increase overall costs of sinusitis-related
care.
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OBJECTIVE: This study evaluates the cost-effectiveness of four
antimicrobial regimens (e.g., levoﬂoxacin monotherapy, ceftri-
axone monotherapy, ceftriaxone plus a macrolide, and ceftriax-
one plus levoﬂoxacin) for the treatment of patients admitted to
the medical ﬂoor with class IV or V community-acquired pneu-
monia (CAP). METHODS: All adult patients with a principal
discharge diagnosis of pneumonia, admitted to Baptist-Health
System from November 1, 1999 to April 30, 2000 were evalu-
ated. Medical ﬂoor patients who met criteria for Pneumonia
Severity Index (PSI) risk class IV or V were included in this analy-
sis. Total hospital charges were converted to costs using the 
hospital cost-to-charge ratio. Wilcoxon Rank Sum was used to
evaluate associations between antimicrobials received (indepen-
dent variable) and total hospital cost (dependent variable). Cost-
effectiveness ratios were determined by dividing the total
hospital cost by the percent survival. RESULTS: A total of 649
patients were managed on the medical ﬂoor with 415 (64%)
meeting the criteria for PSI risk class IV (N = 274) or V (N =
141) CAP. Costs (median, 25th and 75th quartile) were as
follows: total hospital cost ($4087 [$2590–$6554]), pharmacy
costs ($606 [$366–$1092]), and antibiotic costs ($112
[$66–$184]). Total hospital costs were lowest for levoﬂoxacin
monotherapy (N = 151, $3506 [$2231–$5870]), followed by 
ceftriaxone monotherapy (N = 61, $3758 [$2741–$6071]), 
ceftriaxone plus a macrolide (N = 61, $4163 [$3100–$5726]),
and ceftriaxone plus levoﬂoxacin (N = 38, $4830
[$2934–$7393]) (P = 0.0921). Survival was the highest for
patients who received ceftriaxone plus a macrolide (98%), fol-
lowed by ceftriaxone plus levoﬂoxacin (95%), levoﬂoxacin
monotherapy (94%), and ceftriaxone monotherapy (87%) 
(P = 0.0734). The most favorable cost-effectiveness ratio was
observed for patients who received levoﬂoxacin monotherapy
($3730 per expected cure), followed by ceftriaxone plus a
macrolide ($4248), ceftriaxone monotherapy ($4370), and cef-
triaxone plus levoﬂoxacin ($5367). CONCLUSION: Among
patients admitted to the medical ﬂoor for class IV or V CAP, lev-
oﬂoxacin monotherapy is the most cost-effective antimicrobial
regimen.
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OBJECTIVES: To present pharmacoeconomic evidence support-
ing the relative cost-effectiveness of two pegylated interferon
therapies, compared with the standard interferon and ribavirin
therapy, for hepatitis C treatment. METHODS: Evidence-based
decision analysis based on genotypes, treatment dose and dura-
tion, comparing the pharmacoeconomic beneﬁts of PEGASYS +
COPEGUS (peginterferon alfa-2a + ribavirin) versus REBE-
TRON (interferon alfa-2b + ribavirin) and PEG-Intron +
REBETOL (peginterferon alfa-2a + ribavirin) versus REBE-
TRON. Cost effectiveness is calculated in terms of the cost per
sustained virological response (SVR); timeframe includes the
course of therapy and treatment-free follow-up of 24-weeks. The
model adopts a managed care perspective and includes only
direct costs. Each therapy efﬁcacy rates, total costs, costs asso-
ciated with diagnosis, medical treatment, drug acquisition and
adverse events are calculated for base-case scenario and sensi-
tivity analyses. RESULTS: Drugs accounted for the largest
portion of total costs, followed by adverse events, diagnostic pro-
cedures and medical treatment. The total costs associated with
PEG-Intron+REBETOL ($29,510) compared with REBETRON
($25,864) imply an incremental cost-effectiveness ratio (ICER)
for PEG-Intron+REBETOL versus REBETRON of $60,767.
PEGASYS + COPEGUS provide an increased probability of
treatment success at a lower cost than REBETRON. Compared
with REBETRON, the combination of PEGASYS + COPEGUS
is deemed a dominant strategy. The results of the sensitivity
